Protective effect and pharmacokinetics of dihydromyricetin nanoparticles on oxidative damage of myocardium

• Published in: PloS one Vol. 19; no. 4; p. e0301036
• Main Authors: Du, Lixin, Lu, Huiling, Xiao, Yifei, Guo, Zhihua, Li, Ya
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 16.04.2024; Public Library of Science (PLoS)
• Subjects: Analysis; Animals; Apoptosis; Biology and Life Sciences; Cardiovascular diseases; Care and treatment; Diagnosis; Engineering and Technology; Flavonols; Health aspects; Hydrogen Peroxide - metabolism; Ischemia; Medicine and Health Sciences; Myocardium - metabolism; Myocytes, Cardiac - metabolism; Nanoparticles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism; Pharmacokinetics; Physiology, Pathological; PPAR alpha - metabolism; Prevention; Rats; Research and Analysis Methods; Risk factors; Superoxide; Superoxide Dismutase - metabolism; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0301036

This study aims to investigate the protective mechanism of dihydromyricetin PLGA nanoparticles (DMY-PLGA NPs) against myocardial ischemia-reperfusion injury (MIRI) in vitro and the improvement of oral bioavailability in vivo. DMY-PLGA NPs was prepared and characterized by emulsifying solvent volatilization, and the oxidative stress model of rat H9c2 cardiomyocyte induced by H2O2 was established. After administration, cell survival rate, lactate dehydrogenase (LDH), malondialdehyde (MDA) and superoxide dismutase (SOD) were detected, and the expressions of PGC1α and PPARα were detected by western blot (WB). At the same time, the pharmacokinetics in rats were studied to explore the improvement of bioavailability. DMY-PLGA NPs can significantly increase cell survival rate, decrease LDH and MDA content, increase SOD content and PGC1α、PPARα protein expression. Compared with DMY, the peak time of DMY-PLGA NPs was extended (P<0.1), and the bioavailability was increased by 2.04 times. DMY-PLGA NPs has a significant protective effect on H9c2 cardiomyocytes, which promotes the absorption of DMY and effectively improves bioavailability.